New York University

The Rockefeller University

Other

Johnson & Johnson Gmbh

The Public Health Research Institute

Richard P Novick

Ronald Beavis

Guangyong Ji

Tom W Muir

Patricia Mayville

Steven J Projan

Susan Brown-Skrobot

Hope Forer Ross

Geeta Ram

Provided are modifiedpathogenicity islands of a variety of types and origins. The pathogenicity island are characterized as having a polynucleotide comprising a bacterial pathogenicity island nucleotide sequence (a 'B-PINS') that contains one or more modifications ('modified B-PINS'), that include i) a deletion or disruption of at least one virulence determinant of the B-PINS; and ii) an insertion of at least one cargo sequence. The polynucleotide are capable of being packaged within a bacterium into a phage-like particle that comprises a bacteriophage capsid, tail and tail fiber proteins in the form of an antibacterial drone (&#x201c;ABD&#x201d;). The ABD is capable of infecting bacteria such that at least one cargo sequence is introduced into bacteria infected by the ABD. Pharmaceutical and other compositions the ABDs are also included. Bacteria that make the ABDs are provided, as are isolated and/or purified ABDs. Methods of killing or otherwise modifying bacteria using the ABDs are also provided.

Compositions and methods for non-antibiotic treating of bacterial infections by blocking or disrupting bacterial genes involved in virulence or viability

The present invention provides a cyclic peptide comprising the structure: wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH&#x2014;X-Z-X&#x2014;COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of to an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

[object Object]

The present invention provides a cyclic peptide comprising the structure:wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, R is selected from the group consisting of oxygen, nitrogen, sulfur and carbon, n is 0 to 10 and y is 1 to 10. The present invention also provides a cyclic peptide comprising the amino acid sequence of NH&#x2014;X-Z-X&#x2014;COOH and a cyclic bond between the Z residue and COOH other than a thioester bond, wherein X is selected from the group consisting of an amino acid, an amino acid analog, a peptidomimetic and a non-amide isostere, Z is selected from the group consisting of a synthetic amino acid and a biosynthetic amino acid, n is 0 to 10 and y is 1 to 10. Methods of preparation including a cyclization protocol, and methods of use of the cyclic peptides of the invention are also disclosed.

Staphylococcus peptides for bacterial interference

This invention provides peptides which inhibit agr transcription in and thereby block the expression of virulence factors in , pharmaceutical compositions comprising these peptides, as well as methods for treating or preventing an infection or disease caused by using the peptides of the present invention.

Blocking expression of virulence factors in S. aureus

A class of chemical compounds comprising fatty acid ester derivatives used to inhibit beta-lactamase production by infectious bacteria. These inhibitors have been found to retard the resistance of certain strains of bacteria to beta-lactam antibiotics, such as penicillin, by interfering with the transcription of the beta-lactamase gene and precluding expression of beta-lactamase. In accordance therewith, these inhibitors permit effective treatment of infections of otherwise resistive bacteria with antibiotics.

Growing community of inventors

New York, NY, United States of America

Richard P Novick